secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2026-10-20T10:05:17+00:00
Accession:  0001193125-26-425647
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Rapport's RAP-219 hits Phase 2 primary endpoint in bipolar mania (3.1-pt YMRS gain, p=0.045)
--------------------------------------------------------------------------------

- Phase 2 met primary endpoint: 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045); 15.4-point mean reduction from baseline vs 12.3 on placebo.
- Secondary CGI-BP mania severity improved 0.4 points vs placebo (p=0.024); all 11 YMRS items improved, with 4 reaching nominal significance.
- 253 adults with bipolar I mania enrolled (126 on RAP-219 0.75 mg, 127 placebo); all TEAEs mild or moderate, no SAEs; 3.2% vs 0.8% discontinued for TEAE.
- Plans FDA End-of-Phase 2 meeting in Q1 2027 and two Phase 3 bipolar mania trials starting 2H 2027; FOS FOCUS 1/2 enrolling, PGTCS Phase 3 1H 2027.
- $436.1M in cash, equivalents and short-term investments as of June 30, 2026; runway into 2H 2029, beyond FOS Phase 3 topline data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/0001193125-26-425647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-425647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer